144 related articles for article (PubMed ID: 1278195)
1. Effects of long-term L-dopa therapy on carbohydrate metabolism in patients with Parkinson's disease.
Rosati G; Maioli M; Aiello I; Farris A; Agnetti V
Eur Neurol; 1976; 14(3):229-39. PubMed ID: 1278195
[TBL] [Abstract][Full Text] [Related]
2. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.
Verhagen Metman L; Stover N; Chen C; Cowles VE; Sweeney M
Mov Disord; 2015 Aug; 30(9):1222-8. PubMed ID: 25847690
[TBL] [Abstract][Full Text] [Related]
3. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
Brannan T; Yahr MD
Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
[TBL] [Abstract][Full Text] [Related]
4. Glucose, insulin, and free fatty acid metabolism in Parkinson's disease treated with levodopa.
Van Woert MH; Mueller PS
Clin Pharmacol Ther; 1971; 12(2):360-7. PubMed ID: 5577484
[No Abstract] [Full Text] [Related]
5. Effect of dopamine agonist (Lergotrile mesylate) therapy on twenty-four hour secretion of prolactin in treated Parkinson's disease.
Bell RD; Carruth A; Rosenberg RN; Boyar RM
J Clin Endocrinol Metab; 1978 Oct; 47(4):807-11. PubMed ID: 45469
[TBL] [Abstract][Full Text] [Related]
6. L-dopa-carbidopa: combined therapy for the treatment of Parkinson's disease.
Celesia GG; Wanamaker WM
Dis Nerv Syst; 1976 Mar; 37(3):123-5. PubMed ID: 1253661
[TBL] [Abstract][Full Text] [Related]
7. Abnormal insulin secretion in Parkinson's disease before and during L-dihydroxyphenylalanine (L-dopa) therapy.
Van Woert MH; Mueller PS; Ambani LM; Rathey U
J Endocrinol; 1973 Dec; 59(3):523-34. PubMed ID: 4761683
[No Abstract] [Full Text] [Related]
8. Managing Parkinson's disease with continuous dopaminergic stimulation.
Wolters E; Lees AJ; Volkmann J; van Laar T; Hovestadt A
CNS Spectr; 2008 Apr; 13(4 Suppl 7):1-14; quiz 15-6. PubMed ID: 18408654
[TBL] [Abstract][Full Text] [Related]
9. Absence of relationships between L-dopa plasma levels and therapeutic effect in Parkinson's disease treated with L-dopa.
Algeri S; Ruggieri S; Miranda F; Casacchia M; Morselli PL; Agnoli A
Eur Neurol; 1976; 14(3):219-28. PubMed ID: 1278194
[TBL] [Abstract][Full Text] [Related]
10. Hypotensive effect of long-term levodopa in patients with Parkinson's disease.
Iwasaki S; Hamaguchi K; Iwasaki A; Takakusagi M; Narabayashi Y
Eur Neurol; 1990; 30(4):194-9. PubMed ID: 2209672
[TBL] [Abstract][Full Text] [Related]
11. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
Podiwinsky F; Mentasti M; Riederer P; Birkmayer W
Wien Klin Wochenschr; 1979 May; 91(10):332-7. PubMed ID: 452602
[TBL] [Abstract][Full Text] [Related]
12. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.
Moreau C; Meguig S; Corvol JC; Labreuche J; Vasseur F; Duhamel A; Delval A; Bardyn T; Devedjian JC; Rouaix N; Petyt G; Brefel-Courbon C; Ory-Magne F; Guehl D; Eusebio A; Fraix V; Saulnier PJ; Lagha-Boukbiza O; Durif F; Faighel M; Giordana C; Drapier S; Maltête D; Tranchant C; Houeto JL; Debû B; Azulay JP; Tison F; Destée A; Vidailhet M; Rascol O; Dujardin K; Defebvre L; Bordet R; Sablonnière B; Devos D;
Brain; 2015 May; 138(Pt 5):1271-83. PubMed ID: 25805645
[TBL] [Abstract][Full Text] [Related]
13. IPX066 , a mixed immediate/sustained-release levodopa preparation for Parkinson's disease.
Ondo W
Expert Opin Pharmacother; 2014 Oct; 15(14):2081-5. PubMed ID: 25146967
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of Parkinson's syndrome with L-dopa and L-carbidopa (author's transl)].
Hanzal F
MMW Munch Med Wochenschr; 1976 May; 118(20):653-6. PubMed ID: 818540
[TBL] [Abstract][Full Text] [Related]
16. Effect of L-DOPA on endogenous histamine metabolism.
Sharpless NS; Muenter MD; Tyce GM
Med Biol; 1975 Apr; 53(2):85-92. PubMed ID: 1152552
[TBL] [Abstract][Full Text] [Related]
17. Levodopa alone compared with levodopa-sparing therapy as initial treatment for Parkinson's disease: a meta-analysis.
Xie CL; Zhang YY; Wang XD; Chen J; Chen YH; Pa JL; Lin SY; Lin HZ; Wang WW
Neurol Sci; 2015 Aug; 36(8):1319-29. PubMed ID: 25981231
[TBL] [Abstract][Full Text] [Related]
18. L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room.
Paul R; Borah A
Biochim Biophys Acta; 2016 Sep; 1860(9):1989-97. PubMed ID: 27318154
[TBL] [Abstract][Full Text] [Related]
19. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C
Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304
[TBL] [Abstract][Full Text] [Related]
20. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
Warren Olanow C; Kieburtz K; Rascol O; Poewe W; Schapira AH; Emre M; Nissinen H; Leinonen M; Stocchi F;
Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
